MIRA Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

MIRA Pharmaceuticals şirketinin toplam hissedar öz sermayesi $3.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $4.3M ve $692.8K dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$4.14m
Eşitlik	US$3.57m
Toplam yükümlülükler	US$692.83k
Toplam varlıklar	US$4.27m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

Nov 19

We're Hopeful That MIRA Pharmaceuticals (NASDAQ:MIRA) Will Use Its Cash Wisely

Jul 24

Recent updates

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

Nov 19

We're Hopeful That MIRA Pharmaceuticals (NASDAQ:MIRA) Will Use Its Cash Wisely

Jul 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MIRA 'nin kısa vadeli varlıkları ( $4.2M ) kısa vadeli yükümlülüklerini ( $692.8K ) aşıyor.

Uzun Vadeli Yükümlülükler: MIRA un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MIRA borçsuzdur.

Borcun Azaltılması: MIRA un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MIRA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: MIRA un, serbest nakit akışı her yıl % 29.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

MIRA Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

We're Hopeful That MIRA Pharmaceuticals (NASDAQ:MIRA) Will Use Its Cash Wisely

MIRA Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

MIRA Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

CEO & Chairman notifies of intention to sell stock

MIRA Pharmaceuticals, Inc. Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

New major risk - Financial position

MIRA Pharmaceuticals, Inc.'s Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

New minor risk - Shareholder dilution

MIRA Pharmaceuticals, Inc. Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals, Inc. Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-Ind Meeting Request to FDA

MIRA Pharmaceuticals, Inc. Achieves 100% Reversal of Neuropathic Pain with Oral Ketamir-2 in Breakthrough Study

Mira Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for Ind Submission by Year-End

MIRA Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $19.268571 million.

MIRA Pharmaceuticals, Inc., Annual General Meeting, Sep 12, 2024

MIRA Pharmaceuticals, Inc. Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

We're Hopeful That MIRA Pharmaceuticals (NASDAQ:MIRA) Will Use Its Cash Wisely

MIRA Pharmaceuticals, Inc. Announces New Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2

New major risk - Share price stability

Mira Pharmaceuticals, Inc. Announces Promising Results for Mira-55 in Multiple Preclinical Tests Compared to THC

MIRA Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

MIRA Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

MIRA Pharmaceuticals, Inc. Announces DEA Rules Mira-55, A Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as A Controlled Substance

Mira Pharmaceuticals, Inc. Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

Mira Pharmaceuticals Inc. Announces Appointment of Itzchak Angel as Chief Scientific Advisor

MIRA Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis from the Board of Directors and as Part-Time General Counsel

MIRA Pharmaceuticals, Inc. Releases Breakthrough Data from Artificial Intelligence Simulations

MIRA Pharmaceuticals, Inc. Approves Appointment of Michael Jerman to the Board

MIRA Pharmaceuticals, Inc. Announces Board Changes

MIRA Pharmaceuticals, Inc. Announces Board Changes

High number of new and inexperienced directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin